Regenerative medicine company Mesoblast Limited today reported that its Japanese partner, JCR Pharmaceuticals Co Ltd , has filed with the Japanese Pharmaceuticals and Medical Devices Agency to receive approval for manufacturing, marketing, and product registration of the allogeneic or "off-the-shelf" Mesenchymal Stem Cell product JR-031 for the treatment of acute graft versus host disease in children and adults. The product registration filing by JCR will be subject to a priority review as JR-031 has been granted orphan drug status.
http://ift.tt/YTUp1v
http://ift.tt/YTUp1v
No comments:
Post a Comment